@article{JTD21552,
author = {Kazumi Nishino and Shuichi Ohe and Masanori Kitamura and Kei Kunimasa and Madoka Kimura and Takako Inoue and Motohiro Tamiya and Toru Kumagai and Shin-ichi Nakatsuka and Taiki Isei and Fumio Imamura},
title = {Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {6},
year = {2018},
keywords = {},
abstract = {Nivolumab, a fully humanized monoclonal IgG4 antibody blocking programmed cell death-1 (PD-1), has demonstrated improved survival over docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) (1,2). Vitiligo-like depigmentation is a well described immune-related adverse event (irAE) in melanoma patients receiving immunotherapy with PD-1 inhibitors but it’s rare in NSCLC (3). We experienced a rare case of metastatic NSCLC who developed vitiligo-like lesions during nivolumab treatment after excess sunburn. We presented clinical course of this patient with the data of histological and immunohistochemical analysis of the skin lesions.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/21552}
}